IMCD Malaysia acquires Euro Chemo-Pharma to accelerate growth in life science markets
ROTTERDAM, The Netherlands (19 May 2023) – IMCD N.V. ("IMCD" or "Company"), a leading distributor, formulator, and solutions provider of speciality chemicals and ingredients, today announces that IMCD has signed an agreement to acquire 100% of the shares of the speciality distribution company, Euro Chemo-Pharma Sdn Bhd ("Euro Chemo-Pharma") and its wholly owned subsidiary, Biofresh Green Sdn Bhd ("Biofresh").
Euro Chemo-Pharma was founded in Malaysia in 1975, offering a wide range of products, mainly food, pharmaceutical and personal care applications. Headquartered in Penang, with offices and warehouses also in Kuala Lumpur and Johor, it ensures the full coverage of the Malaysian market. The company also represents leading global suppliers providing its customers with an extensive portfolio backed by in-depth formulation expertise. With a generated revenue of approximately MYR 270 million (ca. EUR 55 million) in the financial year that ended on June 30, 2022, Euro Chemo-Pharma adds approximately 124 employees to the IMCD Malaysia team and an application laboratory in Penang.
Additionally, Euro Chemo-Pharma’s subsidiary, Biofresh, includes blending, mixing, and compounding of food and flavour ingredients and holds the Halal certification.
"Euro Chemo-Pharma's strategic positioning is fully aligned with IMCD, providing us the complementary portfolio to accelerate growth in the Malaysian market," remarked Andreas Igerl, President at IMCD APAC. "In addition, we aim to leverage the suppliers’ synergies we gain from them to develop further our life science business in the Asia Pacific markets," concluded Igerl.
"We have managed to grow the company to be the largest and most efficient speciality ingredients distributor in Malaysia," commented Jeryl Tan, Executive Director at Euro Chemo-Pharma. "With the mindset that if you don’t step forward, you are always in the same place, we believe that IMCD would be our best partner in the journey to drive growth and provide an exciting new home for our people," concluded Tan.
The closing of the transaction is subject to customary closing conditions and is expected to take place in the last quarter of 2023.
Attached, the press release in pdf format, the main visual, and the photo caption.
Attachments
- Photo - IMCD Malaysia acquires Euro Chemo-Pharma to accelerate growth in life science markets
- Press Release - IMCD Malaysia acquires Euro Chemo-Pharma to accelerate growth in life science markets
- Photo Caption_IMCD Malaysia acquires Euro Chemo-Pharma to accelerate growth in life science markets
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DSV, 1073 - SHARE BUYBACK IN DSV A/S28.11.2023 10:43:00 CET | Press release
Company Announcement No. 1073 On 24 October 2023, we initiated a share buyback programme, as described in Company Announcement No. 1066. According to the programme, the company will in the period from 24 October 2023 until 31 January 2024 purchase own shares up to a maximum value of DKK 2,500 million, and no more than 4,000,000 shares, corresponding to 1.83% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The following transactions have been recorded under the programme: Trading dayTrading platformNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-19815,2971,055.73860,736,39420:20 November 2023AQEU1,7251,089.31CEUX5,7061,089.9
Notification of managers and closely related parties’ transactions with A.P. Møller - Mærsk A/S shares in connection with share buy-back program28.11.2023 10:36:32 CET | Press release
In connection with the announced share buy-back program in A.P. Møller - Mærsk A/S, A.P. Møller Holding A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Attachment APMM Share buy-back APMH sale 27112023
Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med A.P. Møller - Mærsk A/S aktier i forbindelse med aktietilbagekøbsprogram28.11.2023 10:36:32 CET | pressemeddelelse
I forbindelse med det annoncerede aktietilbagekøbsprogram i A.P. Møller - Mærsk A/S sælger A.P. Møller Holding A/S løbende aktier pro rata og markedet informeres følgeligt herom - se vedhæftede fil. Vedhæftet fil APMM Aktietilbagekøbsprogram APMH salg_27112023
RESULT OF RIKSBANK CERTIFICATE SALE28.11.2023 10:15:00 CET | Press release
AuctionAuction resultsAuction date2023-11-28Start date2023-11-29Maturity date2023-12-06Interest rate4.00 %Offered volume, SEK bn1 017.0Total bid amount, SEK bn923.6Accepted volume, SEK bn923.6Number of bids19Percentage allotted, %100.00
Ekstraordinære indfrielser (CK93)28.11.2023 10:00:00 CET | pressemeddelelse
KommuneKredit offentliggør hermed oplysninger om ekstraordinære indfrielser (CK93) pr. 24. november 2023. For yderligere informationer om dataformat og –indhold henvises til Nasdaqs hjemmeside. Med venlig hilsen KommuneKredit Vedhæftet fil Fortindf-24112023